Leukemia, Myelodysplasia, Transplantation
News
Nilotinib beats imatinib in newly diagnosed CML
NEW ORLEANS—New data indicate a trend for longer overall survival and event-free survival in newly diagnosed chronic myeloid leukemia (CML)...
News
So far, so good with dasatinib plus chemo in core binding factor AML
Major finding: At 12 months, event-free survival was 85% and overall survival was 89%.Data source: A prospective phase II study in 61 patients...
News
Idelalisib plus rituximab boosts survival in relapsed chronic lymphocytic leukemia
Major finding: Median progression-free survival was 5.5 months with rituximab and placebo and has not been reached with idelalisib plus rituximab...
News
VIDEO: What's ahead for chronic myelogenous leukemia?
Conference Coverage
Gene therapy for SCID-X1 may successfully reset immune system
Major finding: Of nine boys with X-linked severe combined immunodeficiency who were treated with gene therapy, seven patients have evidence of T-...
News
ASH introduces its Choosing Wisely list
Conference Coverage
Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients
Major finding: Progression-free survival was 15.2 months with combination rituximab vs. 26.7 months with combination obinutuzumab (HR, 0.39; P...
Conference Coverage
Resurrected gemtuzumab shows benefit against pediatric AML
Major finding: Three-year event-free survival rates were 53% for children and young adults treated with gemtuzumab ozogamicin added to a standard...
Video
ASH13: The ENESTnd trial update
Conference Coverage
Age barrier falls for half-matched bone marrow transplants
Major finding: Patients in their 50s, 60s, and 70s had similar estimated 2-year progression-free survival (39%, 36%, 39%) and overall survival (51...
News
Ethnic differences in stem cell transplants may be narrowing
Major finding: Just 20% of non-white patients in the study had a fully-matched donor available, while 69% of white northern European patients did...